ADIM
GSK icon

Alpha DNA Investment Management’s GSK GSK Stock Holding History

Alpha DNA Investment Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-320
Closed -$14K – 325
2021
Q1 		$14K Hold
320
– – 0.02% 273
2020
Q4 		$14K Buy
+320
New +$14.7K 0.01% 280

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alpha DNA Investment Management's GSK Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of GSK (GSK) in Q2 2021, closing a stake of 320 shares — an estimated $14K sold.

Alpha DNA Investment Management first reported a position in GSK in Q4 2020 and held it in 2 quarters. The position peaked at $14K in Q1 2021. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 320 GSK shares in Q2 2021, an estimated $14K.
  • Alpha DNA Investment Management first reported a position in GSK in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's GSK position peaked at $14K in Q1 2021.
  • 798 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.